Literature DB >> 9851885

Modification of development by the CFTR gene in utero.

S L Morrow1, J E Larson, S Nelson, H S Sekhon, T Ren, J C Cohen.   

Abstract

The in utero infection of rats at 16-17 days gestation with a recombinant adenovirus carrying the human cystic fibrosis transmembrane conductance regulator (cftr) gene resulted in altered lung development and morphology. These structural alterations prompted an evaluation of concurrent functional changes in the cftr-treated lung. CFTR protein could be detected in treated lungs for up to 30 days postinfection, although it was not detected in the intestines at this time. Increased levels of secreted glycoconjugates and lipids were found in lungs treated in utero with human cftr and large vacuoles containing glycoconjugates were detected within cells of the intestines. The scope and durability of these changes suggested that in utero cftr treatment influenced the activity of secretory cells in the developing lung. Altered secretory products in the lungs of cystic fibrosis patients are thought to be associated with increased susceptibility to Pseudomonas aeruginosa infection. We challenged 3-month-old rats (treated in utero with the human cftr gene) with a lethal, intratrachial dose of this bacteria. Rats treated with cftr exhibited enhanced resistance to Pseudomonas infection when compared to controls. These animals displayed little or no associated inflammatory response. No evidence of the adenovirus transgene was detectable at the time of P. aeruginosa inoculation, indicating that continuous ectopic expression of hcftr was not required for enhanced protection. These data demonstrate that in utero, cftr expression influenced the development and function of cells involved in the primary host defense against bacterial infection in the lung. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9851885     DOI: 10.1006/mgme.1998.2755

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  11 in total

1.  In utero gene therapy.

Authors:  J E Larson; J C Cohen
Journal:  Ochsner J       Date:  2000-04

2.  Cystic fibrosis: more questions than answers.

Authors:  Janet E Larson
Journal:  Ochsner J       Date:  2003

3.  Transient in utero knockout (TIUKO) of C-MYC affects late lung and intestinal development in the mouse.

Authors:  J Craig Cohen; Donald K Scott; James Miller; Jianxuan Zhang; Pengbo Zhou; Janet E Larson
Journal:  BMC Dev Biol       Date:  2004-04-16       Impact factor: 1.978

4.  Pathophysiologic consequences following inhibition of a CFTR-dependent developmental cascade in the lung.

Authors:  J Craig Cohen; Janet E Larson
Journal:  BMC Dev Biol       Date:  2005-02-04       Impact factor: 1.978

5.  Adult onset lung disease following transient disruption of fetal stretch-induced differentiation.

Authors:  Joseph J Hudak; Erin Killeen; Ashok Chandran; J Craig Cohen; Janet E Larson
Journal:  Respir Res       Date:  2009-05-06

6.  The Peter Pan paradigm.

Authors:  J Craig Cohen; Janet E Larson
Journal:  Theor Biol Med Model       Date:  2008-01-08       Impact factor: 2.432

7.  Transient in utero disruption of cystic fibrosis transmembrane conductance regulator causes phenotypic changes in alveolar type II cells in adult rats.

Authors:  Ashraf Gad; Delon L Callender; Erin Killeen; Joseph Hudak; Malgosia A Dlugosz; Janet E Larson; J Craig Cohen; Avinash Chander
Journal:  BMC Cell Biol       Date:  2009-03-31       Impact factor: 4.241

8.  In utero recombinant adeno-associated virus gene transfer in mice, rats, and primates.

Authors:  Deiadra J Garrett; Janet E Larson; Daisy Dunn; Luis Marrero; J Craig Cohen
Journal:  BMC Biotechnol       Date:  2003-09-30       Impact factor: 2.563

9.  Long term physiologic modification using rAAV in utero gene-therapy.

Authors:  Deiadra J Garrett; J Craig Cohen; Janet E Larson
Journal:  Genet Vaccines Ther       Date:  2004-05-19

10.  CFTR and Wnt/beta-catenin signaling in lung development.

Authors:  J Craig Cohen; Janet E Larson; Erin Killeen; Damon Love; Ken-Ichi Takemaru
Journal:  BMC Dev Biol       Date:  2008-07-06       Impact factor: 1.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.